Exercise and the immune system: taking steps to improve responses to cancer immunotherapy

Michael P Gustafson,1 Courtney M Wheatley-Guy,2 Allison C Rosenthal,3 Dennis A Gastineau,1 Emmanuel Katsanis,4 Bruce D Johnson,2 Richard J Simpson5

ABSTRACT
The remarkable success of cancer immunotherapies has provided new hope to cancer patients. Unfortunately, a significant proportion of patients remain unable to respond to immunotherapy or maintain durable clinical responses. The lack of objective responses likely results from profound immune dysfunction often observed in patients with cancer. There is substantial evidence that exercise and physical activity can reduce incidence and improve outcomes in cancer patients. As the immune system is highly responsive to exercise, one potential avenue to improve immune function is through exercise and physical activity. A single event of dynamic exercise results in the substantial mobilization of leukocytes with increased functional capacities into the circulation. Chronic, or long-term, exercise leads to higher physical fitness in terms of greater cardiorespiratory function and/or muscle strength and endurance. High aerobic capacity, as measured by maximal oxygen uptake, has been associated with the reduction of dysfunctional T cells and improvements in the abundance of some T cell populations. To be sure, however, the mechanisms of exercise-mediated immune changes are both extensive and diverse. Here, we examine the evidence and theorize how acute and chronic exercise could be used to improve responses to cancer immunotherapies including immune checkpoint inhibitors, dendritic cell vaccines, natural killer cell therapies, and adoptive T cell therapies such as chimeric antigen receptor (CAR) T cells. Although the parameters of optimal exercise to yield defined outcomes remain to be determined, the available current data provide a compelling justification for additional human studies and clinical trials investigating the adjuvant use of exercise in immuno-oncology.

INTRODUCTION
The promise of cancer immunotherapy is rapidly transforming the field of oncology. The accumulation of vast experimental data derived from animal models and from clinical trials demonstrates that there are multiple aspects to generate successful durable clinical responses in patients receiving immunotherapy: the specificity, magnitude, and diversity of the immune response all contribute to the formation of immunological memory. One of the major obstacles to successful responses to immunotherapy is that systemic immunity in cancer patients is often impaired as a result of multiple diverse mechanisms. Emerging evidence suggests that optimal systemic immunity is critical for longer overall survival of patients with cancer and durable clinical responses to immunotherapy.1-3 A large body of evidence suggests that exercise and physical activity improves the overall health of patients with cancer and may prolong survival.4-7 Physical activity is defined as any bodily movement produced by skeletal muscles or that requires contraction of your muscles and energy expenditure.8 Exercise is a form of physical activity that involves repetitive bodily movement done in a planned and structured manner with the goal of improving or maintaining one or more components of physical health or fitness.9 Since there is such a strong association between exercise and improved outcomes in cancer patients, we suggest that a complementary approach to improving responses to immunotherapies is to strengthen systemic immunity and patient immune responses via exercise thereby allowing a more potent therapeutic response. There have been numerous studies recently published that reveal some provocative data on how exercise influences immune cell populations and their function. As such, the purpose of this review is to appraise the literature and present the scientific premise by which physical activity and exercise has the potential to restore and optimize the immune system’s responses to cancer immunotherapy. Additionally, we will assess the strategy of utilizing exercise regimens to improve outcomes in patients receiving cancer immunotherapy. While we will focus primarily on human data, animal models will be discussed to shed light on potential mechanisms and to provide guidance on future investigations where there are gaps in the literature in human studies.
EXERCISE AS MEDICINE

The use of exercise as a medicine requires an understanding of the appropriate dose of exercise to achieve the desired effect. On an individual basis, the optimal health effects of physical activity and exercise are dependent on their appropriate dose in relation to their physical fitness. Exercise can be performed in three general categories: acute exercise, exercise training, and chronic exercise. Acute exercise encompasses single defined events with repetitions over a short period of time. Exercise training (high intensity interval training, for example) typically involves consistent frequent events over the course of many weeks to months. Chronic exercise describes consistent and frequent exercise over a long period of time (generally over a year). While physical activity and exercise are often used interchangeably, these terms are used to reflect activities related to fitness. The term physical fitness relates to a ‘set of attributes that people have or achieve that relates to the ability to perform physical activity’ as defined by the US Department of Health and Human Services. Physical fitness has multiple components: cardiorespiratory fitness, muscular strength, muscular endurance, body composition and flexibility. The exercise dose is highly dependent on the FITT principles (Frequency, Intensity, Time, and Type) and these aspects of exercise must be considered for is crucial for generating desired outcomes.11 The heterogeneous and inconsistent results that are often observed when exercise is used as medicine results from the variability of the FITT principles applied to the study design. This variability is perhaps one of the most significant problems in the exercise field and prevents simplifying the recommended amounts of exercise that are associated with physiological benefits. Fortunately, this need has been recognized as we and other groups in the field have published studies to optimize and standardize methods to quantify the exercise dose and how to put these concepts into clinical practice, we would refer the reader to an excellent review by Wasfy and Baggish.21

THE IMMUNE SYSTEM IS HIGHLY RESPONSIVE TO EXERCISE

Exercise improves immune function in part by mitigating the detrimental effects of immune dysfunction caused by both aging (immunosenescence and inflamming), and obesity (both inflammatory and immunosuppressive mechanisms). However, exercise also induces substantial changes to both the innate and adaptive immune responses. Before these mechanisms are discussed, however, it is important to appreciate the nexus between skeletal muscle and the immune system.

The myokine connection

Muscle has been recognized as a major secretory organ as over 300 proteins have been identified to be secreted from resting muscle. As nearly half of the human body mass is composed of muscle, the muscle releases a substantial amount of proteins that regulate many physiological processes. Many of these proteins have been defined as myokines, or muscle-derived cytokines. In addition to supporting glucose metabolism and myogenic growth, these myokines mediate beneficial functions on the immune system. The most prominent myokines relevant to supporting both muscle and immune health are interleukin 4 (IL-4), IL-6, IL-7, IL-8, and IL-15. IL-6 released from contracting muscles rises exponentially with increasing intensity and duration of exercise to nearly 100 times the baseline plasma levels in peripheral blood. While IL-6 has both prominent proinflammatory and anti-inflammatory properties, in the context of exercise, the induction of IL-6 produces an anti-inflammatory effect, without the preceding increase in tumor necrosis factor α (TNFα) levels observed in proinflammatory conditions, and functions to stimulate gluconeogenesis. Circulating anti-inflammatory cytokines like IL-1 receptor antagonist and IL-10 are amplified with concurrent declines in TNF-α because of exercise-mediated IL-6 release. Chronic exercise also appears to reduce resting levels of IL-6 in circulation.

IL-15 and IL-7, two cytokines critical for maintaining T cell homeostasis, are also highly expressed and secreted by exercising skeletal muscle. Vigorous acute exercise leads to a strong induction of both mRNA levels and circulating plasma levels of these cytokines. IL-7 and IL-15 are critical T cell homeostatic cytokines that coordinate to replenish naive and memory cell populations. IL-7 provides survival and proliferative signals for recent thymic emigrants (RTE) and naïve T cells but also supports...
the generation and persistence of memory cells following antigen exposure. IL-15 appears to primarily support the expansion of memory T cells and CD8+ memory T cells are particularly sensitive to IL-15. Muscle-specific ablation of IL-15 in mice led to reduced total CD8+ T cells which exhibited higher markers of exhaustion including Programmed cell death protein (PD-1), CD244, LAG-3 and TIGIT. Wallace et al found that IL-15 and IL-7 were both capable of promoting cell survival through upregulating antiapoptotic mechanisms and telomerase activity to preserve telomere length. The cytokines also stimulated proliferation without inducing differentiation of T cells by phenotypic change or acquisition of effector function. In support of the coordination between these two cytokines, Cieri et al found that IL-7 promotes the induction of a self-renewing, stem-cell-like memory CD8+ T cell subset (Tscm) and IL-15 subsequently was required for the expansion of these specialized memory subsets. IL-15 is also critical for proper proliferation and differentiation of natural killer (NK) cells. The connection of muscle-derived cytokines and immune effector cell homeostasis is an area ripe for further investigation as it has been proposed that the diminished secretory output of these cytokines as a result of aging-related sarcopenia is a critical mechanism for the development of immune senescence. Overall, it is apparent that the induction of muscle-derived cytokines supports healthy immune effector cell populations by maintaining a proper balance of pro-inflammatory and anti-inflammatory mediators and by supporting appropriate homeostatic mechanisms.

**Acute exercise: increased mobilization of leucocytes**

In response to acute dynamic exercise (eg, running, cycling, rowing), there is a robust and almost instantaneous mobilization of leucocytes to the blood compartment. While granulocytes account for a large proportion of the mobilized cells, both the granulocyte to lymphocyte and monocyte to lymphocyte ratios are reduced indicating that exercise preferentially recruits lymphocytes to the bloodstream. There is also a preferential mobilization of lymphocyte subsets in the order of greatest magnitude of relative change—NK-cells, gamma delta (γδ) T-cells, CD8+ T cells, CD4+ T cells and B-cells. Within these subsets, there also appears to be a preferential mobilization of those cell types with phenotypic characteristics of high differentiation and migration potential. Lymphocytes also display rapid egress kinetics with NK-cells in particular, despite increasing threefold to fivefold during the exercise, reverting to near resting levels within just a few minutes after exercise cessation. In the early phase of exercise recovery (eg, 1 hour after exercise cessation), blood T-cells exhibit an activated cytokine-secreting profile and NK-cells are better equipped to kill certain hematologic cancer cell lines in vitro. Similarly, γδ T-cells mobilized with exercise expand more readily when stimulated with bisphosphonate antigens resulting in phenotypic shifts that promote increased cytotoxicity against a range of hematologic tumor cell lines including those derived from leukemia, lymphoma and multiple myeloma. The release of cytokines cytokines and other hormones are largely involved in the mobilization, priming and/or redistribution of activated effector lymphocytes in response to acute exercise and several groups, including ours, have suggested that this acute stress response should be harnessed for therapeutic purposes such as boosting immune responses to vaccination or obtaining more potent immune cell products from the blood for cellular therapy.

### Acute exercise: increased immune surveillance

Since exercise redeploys massive numbers of lymphocytes with each bout, acute exercise has been purported to increase immune surveillance due to the frequent mobilization and redistribution of effector lymphocytes. This idea was best demonstrated by Pedersen et al who reported that voluntary wheel running reduced tumor incidence and growth by ~60% across five different murine tumor models via mechanisms that are dependent on the catecholamine-induced mobilization and redistribution of NK-cells. Greater numbers of NK-cells were found in the tumors of exercised mice compared with controls, but not when mice were administered propranolol (non-selective beta-blocker) to prevent catecholamine-mediated NK-cell mobilization. Further, the exercise effects were replicated in non-exercised mice injected with daily doses of epinephrine underscoring the importance of catecholamines in facilitating immune cell mobilization and redistribution. The idea that each exercise bout contributes to improvements in antitumor immune surveillance is bolstered by a previous study from our group that T-cells mobilized into the blood with acute exercise are more responsive to ex vivo stimulation with autologous antigen presenting cells pulsed with tumor associated antigens such as the Wilms Tumor antigen (WT1), preferentially expressed antigen in melanoma (PRAME), and melanoma-associated antigen 4 (MAGE-A4). As such, the beneficial effects of chronic exercise may be due to the fact that immune cells are mobilized and redeployed with every exercise bout, thus improving immune surveillance without necessarily altering immune competency at the basal (ie, individual cell) level. Indeed, despite exercise-mobilized NK-cells being shown to play an important role in the antitumor effects of exercise, exercise training interventions in humans often results in little to no changes in NK-cell activity in vitro, although we did report recently that changes in NK-cell function might be more marked in those that show the greatest changes in aerobic fitness following the intervention. We should note here that most studies to date have described the effects of exercise training on ‘static’ endpoints of immune function using standardized in vitro based assays (eg, NK-cell cytotoxicity or T-cell proliferation using cells obtained from resting blood). We contend that immune system adaptations to exercise training might be better observed using ‘dynamic’ endpoints such as the number of NK-cells and...
T-cells that can be mobilized with exercise, and/or the ability of these cells to traffic toward and infiltrate tumors in xenogeneic mouse models.

**Chronic exercise: preserving functional T cells**

Chronic exercise appears to mitigate the detrimental effects on T cells that are caused by a variety of conditions like obesity, aging, and chronic infection. Table 1 lists the phenotypes that can be positively influenced by chronic exercise and phenotypes that have been shown to be correlated with high cardiorespiratory fitness (VO₂max).

### Table 1  T cell phenotypes associated with physical conditions and improved by chronic exercise or exercise training

| T cell phenotype | Associated with obesity and/or physical inactivity | Associated with aging | Associated with chronic infection (ie, CMV) | Associated with physical fitness (VO₂max) | References |
|------------------|-----------------------------------------------|----------------------|------------------------------------------|------------------------------------------|------------|
| CD3⁺ T cells     | ↓                                              |                      |                                          |                                          | 71         |
| CD8⁺ T cells     | ↑                                              |                      |                                          |                                          | 46         |
| CD4⁺CD8 ratio    | ↓                                              | ↓                    |                                          |                                          | 46         |
| γδ T cells       | ↓                                              | ↑                    | ↑                                        | ↑                                        | 46 149     |
| **Naïve T cells**|                                               |                      |                                          |                                          |            |
| CD4⁺CD45RA⁺      | ↓                                              | ↓                    |                                          | ↑                                        | 71 72 150  |
| CD8⁺CD45RA⁺CD27⁺CCR7⁺CD62L⁺ also KLRG1⁺CD28⁺ | ↓                                              | ↓                    |                                          | ↑                                        | 46 71      |
| **Memory T cells**|                                               |                      |                                          |                                          |            |
| CD4⁺CD45RO⁺ Memory | ↑                                              | ↑                    |                                          |                                          | 46 72      |
| CD8⁺CD45RO⁺ Memory T cells | ↑                                              |                      |                                          |                                          | 71         |
| **Central memory T cells**|                                               |                      |                                          |                                          |            |
| CD4⁺CD45RA⁺CCR7⁺ and CD8⁺CD45RA⁺CCR7⁺ | ↑                                              | ↑                    |                                          |                                          | 46 71 150  |
| **Effector memory T cells**|                                               |                      |                                          |                                          |            |
| CD4⁺CD45RA⁺CCR7⁺ and CD8⁺CD45RA⁻CCR7⁻ | ↓                                              | ↑                    |                                          |                                          | 46 71 150  |
| **Effector T cells**|                                               |                      |                                          |                                          |            |
| CD4⁺CD45RA⁺CCR7⁺ and CD8⁺CD45RA⁺CCR7⁺ | ↑                                              | ↑                    |                                          |                                          | 71         |
| **Regulatory/immuno-suppressive T cells**|                                               |                      |                                          |                                          |            |
| CD4⁺CD25⁺Foxp3⁺ or CD127⁺ Regulatory T cells | ↑                                              | ↑                    |                                          |                                          | 46 71      |
| CD4⁺CD28⁺CD57⁺KLRG1⁺ and CD8⁺CD28⁺CD57⁺KLRG1⁺ Senescent T cells | ↑                                              | ↑                    | ↓                                        |                                          | 60 71      |
| CD4⁺PD-1⁺        | ↑                                              |                      |                                          |                                          | 46         |

↑ indicates condition increases phenotype and ↓ indicates condition decreases phenotype.

*Indicates phenotype was not improved on in exercise by Duggal et al.⁷¹

CMV, cytomegalovirus; EMRA, effector memory RA +cells; PBMC, peripheral blood mononuclear cells; VO₂max, maximal oxygen uptake.

In terms of improving responses to cancer immunotherapy, we hypothesize that chronic exercise could improve antitumor responses in multiple ways. First, chronic exercise is associated with lower proportions of senescent T cells and increased proportions of naïve T cells that are needed for optimal immune responses. In a study of over 100 healthy males aged 18–61, our group found a strong association between aerobic fitness (VO₂max) and reduced populations of senescent CD8⁺KLRG1⁺CD28⁺, CD4⁺KLRG1⁺CD57⁺, and CD8⁺KLRG1⁺CD57⁺ T cells.⁶⁰ The loss of CD28 and CD27 and/or the appearance of KLRG1 and CD57 on T cells are indicators of highly differentiated senescent T cells resulting from chronic antigen stimulation and are a classic feature of the aging immune system.⁶⁰–⁶³ T cell senescence is characterized by telomere shortening, impaired IL-2 release, and prolonged DNA damage responses leading to cell cycle arrest.⁶¹ IL-2 regulates homeostatic maintenance of regulatory T cells and differentiation of antigen-activated T cells into effector subsets.⁶⁴ Interestingly, the proliferative defect of
senescent cells may not be overcome by IL-2 or IL-15, but IL-7 has been shown to prevent CD27 and CD28 loss, improve proliferation, and restore IL-2 production to T cells cultured in the presence of tumor cells. The results from our Spielman et al study reveal that high cardiorespiratory fitness is associated with declines in the accumulation of defective T cells that have lost their ability to mediate antitumor responses.

Moreover, our group assessed the abundance and distribution of over 30 T cell phenotypes in sedentary and active men in baseline samples and in response to two types of acute exercise (an incremental maximal cycling test until exhaustion and an endurance cycling test of 45 min at 60% of maximum workload). We found numerous T cell phenotypes associated with obesity/lean body mass (Tregs positively correlated with percent body fat) and physical inactivity (elevated CD4+ memory cells and PD-1+ cells in sedentary individuals) from baseline samples. In addition, we identified two phenotypes that significantly correlated with VO2max; γδ T cells as a percentage of CD3+ T cells, and naïve (CD45RA+CD27+CD62L+CCR7+) cells as a percentage of total CD8+ T cells. γδ T cells are very responsive to IL-15. On IL-15 exposure, these cells are rapidly activated via upregulation of CD69, HLA-DR, and CD56 expression, secrete high levels of IFNγ, become highly proliferative, and demonstrate increased cytotoxicity against tumor cells. CD4+CD8− T cells (or double negative T cells), of which γδ T cells comprise a large proportion of these cells, have also been shown to be responsive to IL-15, whereby IL-15 strongly induced their tumoricidal activity through upregulation of effector molecules including NKG2D, DNAM-1, and NKP30 as well as intracellular perforin and granzyme B. Naïve CD8+ T-cells with a CD45RA+CD27+CD62L+CCR7+ phenotype contain a population of long-lived human memory stem-like T cells (T stem) characterized by additional cell surface markers including the IL-7 receptorα (CD127), CD95, IL-2RB (IL-2 and IL-15 receptor), CXCR3, and LFA-1(70). These cells, which have a naïve cell surface phenotype but have functional attributes of memory cells, have enhanced capacity for self-renewal and a multipotent ability to derive central memory, effector memory and effector T cells. In a humanized mouse model, T stem cells demonstrated superior antitumor activity over other central and effector memory subsets.

Other groups have looked at the influence of chronic exercise on T cell subsets. Duggal et al found higher naïve CD4+, CD8+ T cells, and RTE with lower frequencies of PD-1 and CTLA-4 are the two most common clinically used checkpoint inhibitors. Two recent studies have demonstrated in animal models that the combination of exercise during anti-PD-1 therapy slowed tumor growth to a greater degree than either modality alone. Wennerberg et al in a breast cancer model found that the incorporation of 30 min of treadmill activity 5 days/week during the course of PD-1 blockade/radiation therapy (RT)
decreased tumor-infiltrating myeloid derived suppressor cells (MDSCs) and increased the infiltration of CD8+ T cells thereby shifting the TME from immunosuppressive to a TME more conducive for effector cell function. Tumor growth was significantly slowed in animals that exercised during anti-PD-1/RT compared with sedentary animals receiving the same anti-PD-1/RT regimen. In a patient-derived xenograft (PDX) non-small-cell lung cancer model, Martin-Ruiz et al also found that exercise in combination with PD-1 blockade reduce tumor growth exhibited by diminished tumor cell proliferation and increase tumor necrosis. Interestingly, both studies found that exercise improved immune responses in part by limiting myeloid cell infiltration in the TME. In agreement with another animal breast cancer model, wheel running after the establishment of breast cancer limited the accumulation of MDSCs. Since both polymorphonuclear MDSCs, monocytes MDSCs, and other immunosuppressive myeloid cells strongly negates responses to cancer immunotherapy, exercise may improve immune responses to checkpoint blockade by limiting the effects of these cells. It should be noted that it appears that inactivity and/or obesity may have an opposite effect on the response to checkpoint blockade. In both animal models and human studies, the data suggest that obese individuals with higher BMI actually respond better to checkpoint inhibition. Donnelly et al contend that the impact of BMI on outcomes needs to be carefully scrutinized as many confounding variables (including age, gender, stage, lactate dehydrogenase, performance status, and BRAF mutation status) likely contribute to this phenomenon. Although the preliminary data on the synergistic effect of exercise and checkpoint inhibition looks promising, the variables outlined by Donnelly et al will also likely influence investigations on the use of adjunct exercise in checkpoint blockade therapies.

**Adaptive T cell therapies**

The clinical use of ex vivo expanded T cells has been a mainstay for cancer immunotherapies for decades. Although it is understood that there are differences in the manufacturing of tumor-infiltrating T cells, virus specific T cells, chimeric antigen receptor T (CAR-T) cells, and γδ T cells for therapeutic use, it is likely that the effects of exercise on T cell biology can be applied to each of these treatment modalities. Since acute exercise rapidly mobilizes and increases T cell numbers in peripheral blood, short bouts of exercise may simply be used to increase the numbers of T cells collected from leukapheresis products. Donnelly et al contend that the impact of BMI on outcomes needs to be carefully

---

**Table 2** Potential mechanisms that could be employed to improve responses to immunotherapy via exercise

| Immunotherapy                  | Mode of exercise | Potential mechanisms to support immunotherapy                                                                 |
|--------------------------------|------------------|---------------------------------------------------------------------------------------------------------------|
| Immune checkpoint inhibitors   | Acute/training   | Increase in trafficking and homing of T cells to tumors                                                        |
|                                | Chronic/long term| Diminish the presence of senescent T cells                                                                   |
| Adoptive, CAR, and γδ T cell Therapies | Acute/training | Increase in T cell numbers, including low frequency viral or antigen specific T cells, for ex vivo expansion |
|                                | Chronic/long term| Maintain homeostatic mechanisms for naïve T cell survival via IL-7                                            |
| NK Cell Therapies              | Acute/training   | Increase in cell numbers for ex vivo expansion                                                              |
|                                | Chronic/long term| Prevent obesity-mediated NK cell dysfunction                                                               |
| Cancer vaccines: Dendritic cells and acellular | Acute/training | Increase in cell yield from leukapheresis products                                                          |
|                                | Chronic/long term| Improve maintenance of circulating DCs normally lost during aging                                           |
| DCs, dendritic cells; NK, natural killer; TME, tumor microenvironment. |

---
the completion of the exercise. This phenomenon likely reflects a protective effect of immune cells redistributing into various organ sites as part of a response to stress. These mobilized cells have enhanced functional capacities and if harvested before redeployment into tissues, could also provide a superior population of cells for the manufacturing process. With the improved yields of cells, it is likely that culture times to obtain the desired numbers for dosing can be shortened. Emerging evidence suggests that the antitumor activity of CAR-T cells may be enhanced by shorter culture times. In addition, short term exercise can improve the collection of low-frequency T cells like γδ T cells, virus-specific T cells, and antigen specific T cells.

Prolonged T cell expansion and persistence in vivo are associated with better clinical outcomes in patients treated with T cell therapies. We hypothesize, that the secretion of both are increased after exercise and the elevated levels may improve expansion and persistence in T cell immunotherapies. Preclinical models have shown that IL-15 and IL-7 contribute to superior CAR-T cell proliferation, effector functions, trafficking, survival, and antitumor activity. In patients with advanced stage lymphoma treated with CAR-19 T cells, high serum levels of IL-15 were associated with greater peak CAR-T levels in circulation and lymphoma remissions. One caveat to be noted here, is that a recently published study demonstrated reduced T cell counts in animal models subjected to 6 weeks of exercise training as a result of declining hematopoiesis. While it is unknown about how long lasting these effects are, there will need to be some additional scrutiny in cancer patients to confirm and/or account for a potential drop in T cell counts during a particular bout of exercise or training session. However, the clinical observations in the CAR-T treatment setting provide a very provocative and testable hypothesis that frequent bouts of exercise sustain high levels of IL-7 and IL-15 for optimal expansion and persistence of adoptively transferred T cells. Moreover, by simply engaging in exercise after adoptive transfer therapy, the therapeutic cell products would undergo frequent mobilization and redistribution which is likely to increase their efficacy. Chronic exercise moderates the effects of the aging immune system and likely augments responses to immunotherapy by preserving naïve T cells, reducing the accumulation of senescent T cells, and increasing the frequency of stem-cell like memory T cells. Each of these T cell populations can impact the manufacturing of T cells for clinical trials using ACT/CAR-T cells. The higher ratios of naïve T cells in long-term physically active individuals may be important as high ratios of memory T cells may potentially cause accelerated differentiation of naïve T cells into a KLRG-CD27- senescent phenotype with diminished antitumor activities. The presence of dysfunctional senescent T cells during the manufacturing process could result in lower yield of cells, higher numbers of T cells with insufficient cytokine and cytotoxic capacities, and inhibition of antigen presentation by dendritic cells. Finally, our observations that naïve CD8+ T cells were correlated with VO₂max may likely suggest that long-term exercise, via skeletal muscle release of IL-7 and IL-15, promotes higher frequencies of cells highly responsive to initiating durable cellular immunity. In summary, our groups have independently found T cell populations associated with physical fitness parameters (VO₂max), and obesity-related factors (BMI, % body fat, etc) the findings suggest that the body’s primary cells that mediate antitumor immunity are specifically influenced by physical fitness. As such, the emerging hypothesis that exercise may enhance the efficacy of T cell therapies by restoring the quantity, diversity, and function of T cell subsets in cancer patients is an exciting premise and warrants further study.

NK cell therapies

Due to their diverse functions, NK cells have long been considered a desirable form of cellular immunotherapy. NK cells have performed well clinically in hematologic malignancies and transplant settings. In other settings, the clinical efficacy of NK cells has been inconsistent with many factors likely contributing to this problem. Manufacturing aspects such as low NK cell quantities in the leukapheresis product and poor ex vivo expansion and/or activation are significant obstacles. Once infused, the lack of persistence and in vivo expansion appear to be significant determining factors of whether patients will respond. The collection of a leukapheresis product after acute exercise could potentially solve the manufacturing issues of low yields and ex vivo expansion since the product collected after exercise would contain approximately 5–10 times the amount of primed NK cells compared with routine leukapheresis collections. Exercise can also greatly limit the effects of obesity on NK cells. The excess lipid/fatty acid accumulation causes NK cell dysfunction by directly inhibiting mTOR-mediated glycolysis. Glycolysis and oxidative phosphorylation drive proper NK cell activation and these processes are initiated by cytokines like IL-2, IL-12, and IL-15. IL-2 and IL-15 result in the upregulation of metabolic regulators mTORC and c-Myc resulting in sustained NK cell survival and great antitumor capacities. Since exercise training has been shown to reduce fatty acid levels in obese/sedentary individuals chronic exercise can improve NK cell function by limiting the immunosuppressive effect of obesity on NK cells.

Dendritic cell–based cancer vaccines

Cancer vaccines are used clinically to stimulate the immune system and generate T cells that can recognize tumor antigens and specifically kill tumor cells that
express those antigens. Dendritic cells can be targeted in vivo with tumor antigens (i.e., peptide injection into the intradermal layer of the skin) or by ex vivo cultured antigen-loaded dendritic cells that can also be injected into the intradermal layer. In vaccines manufactured using dendritic cells, circulating monocytes are obtained from leukapheresis collections, purified most commonly by elutriation or immunomagnetic selection, and then placed into ex vivo culture to differentiate the monocytes into dendritic cells. In the acute setting, exercise can be utilized to increase the yield of monocytes from leukapheresis collections. Since monocytopenia has been observed in patients with a variety of cancers, the lack of adequate quantities of monocytes for the manufacturing of dendritic cell vaccines is a significant issue. We demonstrated a threefold increase in the number of circulating monocytes collected from healthy volunteers after they ran on a treadmill until with increasing intensity until volitional exhaustion. Monocytes collected after the exercise exhibited similar cell surface phenotypes, maturation efficiency, and antigen uptake to monocytes taken from subjects without exercise. In addition, healthy volunteers that cycled for 20 min at 80% of VO2 max in a single bout of acute exercise demonstrated an increase in circulating plasmacytoid dendritic cells are also mobilized during acute exercise. Chronic exercise may also reduce the presence of immunosuppressive monocytes in cancer patients. The significant accumulation of these cells in peripheral blood resulting from interactions within the TME can affect the quality of dendritic cell maturation in ex vivo cultures. Since patients with cancer exhibit significant immune dysfunction from the normal aging process and from tumor-derived immunosuppression, physical activity and further exercise training could benefit cancer patients receiving cancer vaccines through the improvement of dendritic cell numbers and enhanced antitumor functions.

INCORPORATION OF EXERCISE INTO CLINICAL APPLICATIONS AND TRANSLATION

Investigators are increasingly incorporating exercise training and physical activity into practice and in clinical trials to improve quality of life, improve cardiorespiratory function, and even as a preventive and/or therapeutic anticancer intervention. Exercise was proposed as an immunotherapy by de Araújo et al as a way to counter immunosenescence in aging cancer patients. Since then, the concept of using exercise to augment cancer therapy, exercise-oncology, has been progressively advocated. While the field is still in its infancy, data from preclinical animal models as well as human studies are providing insight and sound justification into how clinical trials might be designed to incorporate exercise into immunotherapeutic regimens. For example, the study by Pophali et al provides an excellent model for how to measure the impact of exercise in that the group prospectively measured the physical activity in approximately 3000 newly diagnosed lymphoma patients and found that active patients had improved survival vs more sedentary patients. A similar approach and clinical setting may be applied to ask whether increased physical activity, aerobic capacity, or training programs improve responses to immunotherapy. In order to properly use exercise in the oncology setting, several legitimate concerns including feasibility of incorporating exercise training into existing clinical trials, ensuring safe training regimens in patients who are often frail, and patient compliance, must continue to be addressed by the community. In terms of feasibility, perhaps the best setting to introduce exercise is in newly diagnosed patients who are early in their treatment. For patient compliance, new ways of encouraging compliance are also being implemented as the community better understands barriers to exercise in patients. Finally, more published guidelines are becoming available to clinicians to incorporate physical activity in the treatment of cancer patients. Although the incorporation of exercise into clinical trials for patients appears to be quite feasible and safe, there will be some patients with cancer who are unable to exercise or are too sick for exercise.

Another major obstacle to optimizing exercise in the treatment of cancer patients is that it is currently unclear as to what parameters of exercise show the most promise for improving disease outcomes. The FITT principles in exercise are indeed significant and need to be considered as they contribute greatly to the heterogeneity of defining a physiologically effective exercise dose. Dethlefsen et al argue that single bouts of acute exercise are beneficial to the cancer patient, as exercise causes physiological changes, even transiently, that increase the anticancer components of exercise. However, data from the literature suggests that there are considerable differences in outcomes in cancer patients on exercise regimens. There is some evidence that short-term training (<4 months) in patients with cancer does not appear to yield significant benefits on measured outcomes like improved preoperative fitness, aerobic capacity, or chemotherapy completion rates. However, improved cardiorespiratory fitness (VO2max) appears to be one of the most consistent improvements among studies involving cancer patients. In non-cancer patient populations, there is evidence that the immune system (i.e., changes in lymphocyte frequencies) can change in athletes after short-term training programs. In patients with rheumatoid arthritis who completed ten weeks of high-intensity interval training, disease severity was reduced, cardiorespiratory function (VO2max) improved, and circulating inflammatory monocytes were reduced. Moving forward, the data collected from the effects of exercise on cancer patients will be important, as the information will likely guide the design of future studies assessing the impact of exercise on responses to immunotherapy.
FUTURE DIRECTIONS AND CONCLUSIONS

It is understood that much of what we have proposed here needs to be investigated and confirmed (or disproved) before exercise be can incorporated routinely into immunotherapeutic regimens. It is clear that there are many complex aspects to the impact of exercise on immune responses. Also, since most human studies have utilized healthy subjects, similar studies will need to be performed in cancer patients in order to better understand whether exercise can restore systemic immunity in cancer patients in which immune suppression is commonly observed. The preliminary evidence is encouraging to support the hypothesis that exercise can improve immunological fitness to the extent that patients should be able to respond better to immunotherapeutic regimens. Now the difficult task has begun to systematically test these hypotheses in both animal models and in clinical trials. It is hoped that the evidence and scientific premise we have outlined here would provide significant justification to move these studies forward.

Contributors
MPG and RJS contributed to the conception of the work. All authors contributed to the drafting and revising of the work. All authors provided final approval of the work.

Competing interests
No, there are no competing interests.

Patient consent for publication
Not required.

Provenance and peer review
Not commissioned; externally peer reviewed.

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is distributed in accordance with the terms of the license.

REFERENCES
1 Gustafson MP, Lin Y, LaPlant B, et al. Immune monitoring using the predictive power of immune profiles. J Immunother Cancer 2013;1:7.
2 Spitzer MH, Carmi Y, Reticker-Flynn NE, et al. Systemic immunity is required for effective cancer immunotherapy. Cell 2017;168:487–502.
3 Zuazo M, Aznar L, Fernández-Hinjal G, et al. Functional systemic CD4 immunity is required for clinical responses to PD-1/L-1 blockade therapy. EMBO Mol Med 2019;11:e10293.
4 Ashcraft KA, Peace RM, Betof AS, et al. Efficacy and mechanisms of aerobic exercise on cancer initiation, progression, and metastasis: a critical systematic review of in vivo preclinical data. Cancer Res 2016;76:4032–50.
5 Lugo D, Pulido AL, Mihos CG, et al. The effects of physical activity on cancer prevention, treatment and prognosis: a review of the literature. Complement Ther Med 2019;44:9–13.
6 Matthews CE, Moore SC, Arem H, et al. Amount and intensity of leisure-time physical activity and lower cancer risk. J Clin Oncol 2020;38:686–97.
7 Rezende LF,Mde, Sá THde, Markozannes G, et al. Physical activity and cancer: an umbrella review of the literature including 22 major anatomical sites and 770,000 cancer cases. Br J Sports Med 2018;52:826–33.
8 Caspersen CJ, Powell KE, Christenson GM. Physical activity, exercise, and physical fitness: definitions and distinctions for health-related research. Public Health Rep 1985;100:126–31.
9 World Health Organization. Physical activity, 2018. Available: http://www.who.int/dietphysicalactivity/pa/en/
10 Rubin M, Altman L, Lavin CJ, et al. Personalized exercise dose prescription. Eur Heart J 2018;39:2346–55.
11 American College of Sports Medicine. ACSM’s guidelines for exercise testing and prescription. Lippincott Williams & Wilkins, 2013.
12 Lansley KE, Dimenna FJ, Bailey SJ, et al. A ‘new’ method to normalise exercise intensity. Int J Sports Med 2011;32:535–41.
13 Wheatley CM, Kannan T, Bornschlegl S, et al. Conducting maximal and submaximal endurance exercise testing to measure physiological and biological responses to acute exercise in humans. J Vis Exp 2018;140:e58417.
14 Migliay DW, McNaughton LR, Polman R, et al. Criteria for determination of maximal oxygen uptake: a brief critique and recommendations for future research. Sports Med 2007;37:1019–28.
15 Beckers PJ, Possemiers NM, Van Craenenbroeck EM, et al. Comparison of three methods to identify the anaerobic threshold during maximal exercise testing in patients with chronic heart failure. Am J Phys Med Rehabil 2012;91:148–55.
16 American Thoracic Society | American College of Chest Physicians, ATS/ACCP statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003;167:211–77.
17 Strasser B, Burtscher M. Survival of the fittest VO sub 2 max a key predictor of longevity. Front Biosci 2018;23:1505–16.
18 Levine BD, VO2max: what do we know, and what do we still need to know? J Physiol 2008;586:25–34.
19 Boussel R, Gnaiger E, Calbet JAL, et al. Muscle mitochondrial capacity exceeds maximal oxygen delivery in humans. Mitochondrion 2011;11:303.
20 Ainsworth BE, Haskell WL, Leon AS, et al. Compendium of physical activities: classification of energy costs of human physical activities. Med Sci Sports Exerc 1993;25:71–80.
21 Wasyf MM, Baggish AL. Exercise dose in clinical practice. Circulation 2016;133:2297–313.
22 Duggal NA, Niemiro G, Harridge SDR, et al. Can physical activity ameliorate immunosenescence and thereby reduce age-related multi-morbidity? Nat Rev Immunol 2019;19:563–72.
23 Gleeson M, Bishop NC, Stensel DJ, et al. The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. Nat Rev Immunol 2011;11:607–15.
24 Hakim FT, Flomerfelt FA, Boyajidze M, et al. Aging, immunity and cancer. Curr Opin Immunol 2004;16:151–6.
25 Lavin KM, Perkins RK, Jerniolo B, et al. Effects of aging and lifelong aerobic exercise on the immune system and exercise-induced inflammation. J Appl Physiol 2020;128:87–99.
26 Simpson RJ, Lowder TW, Spilmann G, et al. Exercise and the aging immune system. Ageing Res Rev 2012;11:404–20.
27 Stoner L, Rowlands D, Morrison A, et al. Efficacy of exercise intervention for weight loss in overweight and obese adolescents: meta-analysis and implications. Sports Med 2016;46:1737–51.
28 Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol 2012;8:457–65.
29 Bortoluzzi S, Scannapieco P, Cestaro A, et al. Computational reconstruction of the human skeletal muscle secretome. Proteins 2006;62:776–92.
30 Fischer CP. Interleukin-6 in acute exercise and training: what is the biological relevance? Exerc Immunol Rev 2006;12:6–33.
31 Shephard RJ. Cytokine responses to physical activity, with particular reference to IL-6: sources, actions, and clinical implications. Crit Rev Immunol 2002;22:165–82.
32 Pedersen BK, Febbraio MA. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev 2008;88:1379–406.
33 Fiuzza-Luces C, Santos-Lozano A, Joyner M, et al. Exercise benefits in cardiovascular disease: beyond attenuation of traditional risk factors. Nat Rev Cardiol 2018;15:731–43.
34 Quinl LS, Haugk KL, Grabstein KB. Interleukin-15: a novel anabolic cytokine for skeletal muscle. Endocrinology 1995;136:3669–72.
35 Haugen F, Norheim E, Lian H, et al. IL-7 is expressed and secreted by human skeletal muscle cells. Am J Physiol Cell Physiol 2010;298:C807–16.
36 Nielsen AR, Mounier R, Plomgaard P, et al. Expression of interleukin-15 in human skeletal muscle cell effect of exercise and muscle fibre type composition. J Physiol 2007;578:305–12.
37 Tamura Y, Watanabe K, Kantani T, et al. Upregulation of circulating IL-15 by treadmill running in healthy individuals: is IL-15 an endocrine mediator of the beneficial effects of endurance exercise? Endocr J 2011;58:211–5.
38 Fry TJ, Mackall CL. The many faces of IL-7; from lymphopoiesis to peripheral T cell maintenance. J Immunol 2005;174:6571–6.
39 Goldrath AW, Sivakumar PV, Giaccum M, et al. Cytokine requirements for acute and basal homeostatic proliferation of naive and memory CD8+ T cells. J Exp Med 2002;195:1515–22.
40 Wu J, Weissshar N, Hotz-Wagenblatt A, et al. Skeletal muscle antagonizes antiviral CD8+ T cell exhaustion. Sci Adv 2020;6:eaba3458.
41 Wallace DL, Bérard M, Soares MVD, et al. Prolonged exposure of naïve CD8+ T cells to interleukin-7 or interleukin-15 stimulates proliferation without differentiation or loss of telomere length. *Immunology* 2006;119:243–53.

42 Nacle C, Cocciarelli F, et al. IL-7 and IL-15 instruct the generation of human memory stem T cells from naïve precursors. *Blood* 2013;121:573–84.

43 Pfefferle A, Jacobs B, Haroun-Izquierdo A, et al. Deciphering natural killer cell homeostasis. *Front Immunol* 2020;11:612.

44 Nacker D, Ziegler C, Rinnerup J, et al. Skeletal muscle as potential central link between sarcopenia and immune senescence. *EBioMedicine* 2019;49:381–8.

45 Simpson RJ, Kunz H, Agha N, et al. Generation of human memory stem T cells from naive precursors. *J Immunother* Cancer 2017;5:30.

46 Rooney BW, Bigley AB, LaVoy EC, et al. Lymphocytes and monocytes egress peripheral blood within minutes after cessation of steady state exercise: a detailed temporal analysis of leukocyte extravasation. *Physiol Behav* 2018;194:260–7.

47 Bigley AB, Revzani K, Chew C, et al. Acute exercise preferentially redeploys NK-cells with a highly-differentiated phenotype and augments cytotoxicity against lymphoma and multiple myeloma target cells. *Brain Behav Immun* 2019;43:160–70.

48 LaVoy EC, Hussain M, Reed J, et al. T-Cell reprogramming and intracellular cytokine expression following exercise: effects of exercise intensity and cytomegalovirus infection. *Physiol Rep* 2017;5:e13072.

49 LaVoy EC, Bosch JA, Lowder TW, et al. Acute aerobic exercise in humans increases cytokine expression in CD27(-) but not CD27(+) CD8(+) T-cells. *Brain Behav Immun* 2013;27:54–62.

50 Baker FL, Bigley AB, Agha NH, et al. Exercise and the regulation of immune functions. *Exerc Sport Sci Rev* 2014;42:160–71.

51 Simpson RJ, Bigley AB, Agha N, et al. Mobilizing immune cells with exercise for cancer immunotherapy. *Exerc Sport Sci Rev* 2014;42:163–72.

52 Dhahbhar PS, Effects of stress on immune function: the good, the bad, and the beautiful. *Immunol Res* 2007;35:150–5.

53 Pedersen L, Idorn M, Olofsson GH, et al. Voluntary running suppresses tumor growth through epinephrine- and IL-6-dependent NK cell mobilization and redistribution. *Cell Metab* 2016;23:554–62.

54 LaVoy ECP, Bollard CM, Hanley PJ, et al. A single bout of dynamic exercise enhances the expansion of MAGE-A4 and PRAME-specific cytotoxic T-cells from healthy adults. *Exerc Immunol Rev* 2015;21:144–53.

55 Woods JA, Ceddia MA, Wolters BW, et al. Effects of 6 months of moderate aerobic exercise training on immune function in the elderly. *Mech Ageing Dev* 1999;109:1–19.

56 Campbell PT, Wernig MH, Seagraves B, et al. Effect of exercise on in vitro immune function: a 12-month randomized, controlled trial among postmenopausal women. *J Appl Physiol* 2008;104:1848–55.

57 Coletta AM, Agha N, Baker FL, et al. The impact of high-intensity interval exercise training on NK-cell function and circulating myokines for breast cancer prevention among women at high risk for breast cancer. *Breast Cancer Res Treat* 2021, doi:10.1007/s10549-021-06111-z. [Epub ahead of print: 08 Feb 2021].

58 Spielmann G, McFarlin BK, O’Connor DP, et al. Aerobic fitness is associated with higher proportions of senescent blood T-cells in man. *Brain Behav Immun* 2011;25:1521–9.

59 Akbar AN, Henson SM. Are senescence and exhaustion intertwined or unrelated processes that compromise immunity? *Nat Rev Immunol* 2011;11:285–96.

60 Henson SM, Franceschi C, Macaulay R, et al. Klrk1 signaling induces defective Akt (Ser473) phosphorylation and proliferative dysfunction of highly differentiated CD8+ T cells. *Blood* 2009;113:6619–28.

61 Thimme R, Appay V, Koschella M, et al. Increased expression of the NK cell receptor KLRG1 by virus-specific CD8 T cells during persistent antigen stimulation. *J Virol* 2005;79:12112–6.

62 Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. *Nat Rev Immunol* 2012;12:180–90.

63 Brenchley JM, Karandikar NJ, Betts MR, et al. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. *Blood* 2003;101:2711–20.
Ghassemi S, Nunez-Cruz S, O’Connor RS, et al. Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells. *Cancer Immunol Res* 2018;6:1100–9.

Porter DL, Hwang W-T, Frey NV, et al. Chimeric antigen receptor T cells persist without disease sustained remissions in relapsed refractory chronic lymphocytic leukemia. *Sci Transl Med* 2015;7:303ra139.

Louis CU, Savoldo B, Dotti G, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. *Blood* 2011;118:6050–6.

Grossenberg J, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. *Clin Cancer Res* 2011;17:4550–7.

Xu Y, Zhang M, Ramos CA, et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR CD19-T cells and are preserved by IL-7 and IL-15. *Blood* 2014;123:3750–9.

Kochenderfer JN, Somerville RPT, Lu T, et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. *J Clin Oncol* 2017;35:1803–13.

Froedermann V, Rohde D, Courties G, et al. Exercise reduces inflammatory cell production and cardiovascular inflammation via instruction of hematopoietic progenitor cells. *Nat Med* 2019;25:1761–71.

Klebanoff CA, Scott CD, Leonardi AJ, et al. Memory T cell-driven differentiation of naive cells impacts adaptive immunotherapy. *J Clin Invest* 2016;126:318–34.

Huff WX, Kwon JH, Henriquez M, et al. The evolving role of CD8+CD28– Immunosuppressive T cells in cancer immunology. *Int J Mol Sci* 2019;20:3552.

Woan KV, Miller JS. Harnessing natural killer cell antitumor immunity: from the bench to bedside. *Cancer Immunol Res* 2020;8:1093–111.

Tanaka J, Miller JS. Recent progress in and challenges in cellular therapy using T cells for hemato logical malignancies. *Blood* 2020;44:100678.

Rezvani K, Rouce RH. The application of natural killer cell immunotherapy for the treatment of cancer. *Front Immunol* 2015;6:578.

Trevi S, Bross L, Charrier E, et al. Alteration of natural killer cell phenotype and function in obese individuals. *Clin Immunol* 2017;177:12–17.

Michelet X, Dyck L, Hogan A, et al. Metabolic reprogramming of natural killer cells in obesity limits antitumor responses. *Nat Immunol* 2018;19:16–24.

O’Brien KL, Finlay DK. Immuneometabolism and natural killer cell responses. *Nat Rev Immunol* 2019;19:282–90.

Kedia-Mehta N, Choi C, McCrudden A, et al. Natural killer cells integrate signals received from tumour interactions and IL2 to induce robust and prolonged antitumour and metabolic responses. *Immuno metabolism* 2019;1:e190014.

Mao Y, van Hoef V, Zhang X, et al. IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells. *Blood* 2016;128:1475–89.

Johnson NA, Macpherson T, Walshaw DW, et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. *Hepatology* 2009;50:1105–12.

Shojaae-Moradie F, Baynes KCR, Pentecost C, et al. Exercise training reduces free fatty acid availability and improves the insulin sensitivity of glucose metabolism. *Diabetologia* 2007;50:404–13.

Chavan R, Salvador D, Gustafson MP, et al. Untreated stage IV melanoma patients exhibit abnormal monocyte phenotypes and decreased functional capacity. *Cancer Immunol Res* 2014;2:241–8.

Saeed L, Patnaik MM, Begna KH, et al. Prognostic relevance of lymphocyte subtypes: Monocytes and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patients. *Blood Cancer J* 2017;7:e550.

LaVoy ECP, Bollard CM, Hanley PJ, et al. A single bout of dynamic exercise by healthy adults enhances the generation of monocyte-derived dendritic cells. *Cell Immunol* 2015;295:52–6.

Brown FF, Campbell JP, Wadley AJ, et al. Acute aerobic exercise induces a preferential mobilisation of plasmacytoid dendritic cells into the peripheral blood in man. *Physiol Behav* 2018;194:1–8.

Gustafson MP, Lin Y, Bleeker JS, et al. Intratumoral CD14+ cells and circulating CD14+HLA-DRlo/neg monocytes correlate with decreased survival in patients with clear cell renal cell carcinoma. *Clin Cancer Res* 2015;21:4224–33.

Labarbe R, Lin Y, Gustafson MP, et al. Cancer Vaccines in the World of Immune Suppressives Monocytes (CD14+(+)HLA-DRlo/neg) Cells: The Gateway to Improved Responses. *Front Immunol* 2014;5:147.

Parney IF, Gustafson MP, Solseth M, et al. Novel strategy for manufacturing autologous dendritic cell/allogeic tumor lysate vaccines for glioblastoma. *Neurooncol Adv* 2020;2:vdaa105.

Quist M, Langer SW, Lillegard C, et al. Effects of an exercise intervention on patients with advanced inoperable lung cancer undergoing chemotherapy: a randomized clinical trial. *Lung Cancer* 2020;145:76–82.

Koutoukidis DA, Land J, Hackshaw A, et al. Fatigue, quality of life and physical fitness following an exercise intervention in multiple myeloma survivors (MASCOT): an exploratory randomised phase 2 trial utilising a modified Zelen design. *Br J Cancer* 2020;123:187–95.

Belkhet AH, Abdallah AR, Ismail HM, et al. Benefits of aerobic exercise for breast cancer survivors: a systematic review of randomized controlled trials. *Asian Pac J Cancer Prev* 2019;20:3197–209.

Kneis S, Wehrle A, Müller J, et al. It’s never too late - balance and endurance training improves functional performance, quality of life, and alleviates neuropathic symptoms in cancer survivors suffering from chemotherapy-induced peripheral neuropathy: results of a randomized controlled trial. *BMC Cancer* 2019;19:414.

Howden EJ, Bigran A, Beaudry R, et al. Exercise as a diagnostic and therapeutic tool for the prevention of cardiovascular dysfunction in breast cancer patients. *Eur J Prev Cardiol* 2020;26:305–15.

Scott JM, Zabor EC, Schwartz E, et al. Efficacy of exercise therapy on cardiorespiratory fitness in patients with cancer: a systematic review and meta-analysis. *J Clin Oncol* 2018;36:2297–305.

Foulkes SJ, Howden EJ, Antil Y, et al. Exercise as a diagnostic and therapeutic tool for preventing cardiovascular morbidity in breast cancer patients- the breast cancer exercise intervention (Bretix) trial protocol. *BMC Cancer* 2020;20:655.

Iyengar NM, Jones LW. Development of exercise as intervention therapy for cancer: a review. *JAMA Oncol* 2019;5:1620.

de Faria AO, Silva LGR, Fernandes JR, et al. Preventing or reversing immunosenescence: can exercise be an immunomodulator? *Immunotherapy* 2013;5:879–93.

Aschraft KA, Warner AB, Jones LW, et al. Exercise as adjunct therapy in cancer. *Semin Radiat Oncol* 2019;29:16–24.

Hofman Olufson G, Jensen AW, Imdorn M, et al. Exercise on Immuno-Immuno- and Immuno-Oncology: a (future) dynamic duo. *Int J Mol Sci* 2020;21:3816.

Jones LW, Altman CM. Exercise-oncology research: past, present, and future. *Acta Oncol* 2013;52:195–215.

Pophali PA, Ip A, Larson MC, et al. The association of physical activity before and after lymphoma diagnosis with survival outcomes. *Am J Hematol* 2018;93:1543–50.

Turner RR, Steed L, Quirk H, et al. Interventions for promoting habitual exercise in people living with and beyond cancer. *Cochrane Database Syst Rev* 2019;10:CD010192.

Avancini I, Skroe L, Tregnaudo D, et al. “Running with cancer”: A qualitative study to evaluate barriers and motivations in running for female oncological patients. *PLoS One* 2020;15:e0227846.

Sallis R, Franklin B, Joy L, et al. Strategies for promoting physical activity in clinical practice. *Prog Cardiovasc Dis* 2015;57:375–86.

Schmitz KH, Campbell AM, Stiver MM, et al. Exercise is medicine in oncology: engaging clinicians to help patients move through cancer. *CA Cancer J Clin* 2019;69:486–98.

Cormie P, Trevaskis M, Thornton-Benke E, et al. Exercise medicine in cancer care. *Aust J Gen Pract* 2020;49:169–74.

Patel AV, Friedenreich CM, Moore SC, et al. American College of Sports medicine roundtable report on physical activity, sedentary behavior, and cancer prevention and control. *Med Sci Sports Exerc* 2019;51:2391–402.

Segal R, Zwaal C, Green E, et al. Exercise for people with cancer: a clinical practice guideline. *Curr Oncol* 2017;24:40–6.

Hayes SC, Newton RU, Spence RR, et al. The exercise and sports science Australia position statement: exercise medicine in cancer care. *Med J Australia* 2019;211:945–8.

Nij H-J, Pudasaini B, Yuan X-T, et al. Exercise training for patients pre- and Postsurgically treated for non-small cell lung cancer: a systematic review and meta-analysis. *Integr Cancer Ther* 2016;15:2–5.

Dethlefsen C, Pedersen KS, Hojman P. Exercise bout mXH: linking systemic exercise responses to breast cancer control. *Breast Cancer Res Treat* 2017;162:399–408.
141 Karenovics W, Licker M, Ellenberger C, et al. Short-term preoperative exercise therapy does not improve long-term outcome after lung cancer surgery: a randomized controlled study. *Eur J Cardiothorac Surg* 2017;52:47–54.

142 Mijwel S, Bolam KA, Gerrevall J, et al. Effects of exercise on chemotherapy completion and hospitalization rates: the OptiTrain breast cancer trial. *Oncologist* 2020;25:23–32.

143 Boereboom CL, Blackwell JEM, Williams JP, et al. Short-Term pre-operative high-intensity interval training does not improve fitness of colorectal cancer patients. *Scand J Med Sci Sports* 2019;29:1383–91.

144 Jones LW, Liang Y, Pituskin EN, et al. Effect of exercise training on peak oxygen consumption in patients with cancer: a meta-analysis. *Oncologist* 2011;16:112–20.

145 Hornsby WE, Douglas PS, West MJ, et al. Safety and efficacy of aerobic training in operable breast cancer patients receiving neoadjuvant chemotherapy: a phase II randomized trial. *Acta Oncol* 2014;53:65–74.

146 Teixeira AM, Rama L, Carvalho HM, et al. Changes in naive and memory T-cells in elite swimmers during a winter training season. *Brain Behav Immun* 2014;39:186–93.

147 Rama L, Teixeira AM, Matos A, et al. Changes in natural killer cell subpopulations over a winter training season in elite swimmers. *Eur J Appl Physiol* 2013;113:859–68.

148 Bartlett DB, Willis LH, Slietz CA, et al. Ten weeks of high-intensity interval walk training is associated with reduced disease activity and improved innate immune function in older adults with rheumatoid arthritis: a pilot study. *Arthritis Res Ther* 2018;20:127.

149 Pistillo M, Bigley AB, Spielmann G, et al. The effects of age and viral serology on γδ T-cell numbers and exercise responsiveness in humans. *Cell Immunol* 2013;284:91–7.

150 Minuzzi LG, Rama L, Chupel MU, et al. Effects of lifelong training on senescence and mobilization of T lymphocytes in response to acute exercise. *Exerc Immunol Rev* 2018;24:72–84.

141 Teixeira AM, Rama L, Carvalho HM, et al. Changes in naive and memory T-cells in elite swimmers during a winter training season. *Brain Behav Immun* 2014;39:186–93.

147 Rama L, Teixeira AM, Matos A, et al. Changes in natural killer cell subpopulations over a winter training season in elite swimmers. *Eur J Appl Physiol* 2013;113:859–68.

148 Bartlett DB, Willis LH, Slietz CA, et al. Ten weeks of high-intensity interval walk training is associated with reduced disease activity and improved innate immune function in older adults with rheumatoid arthritis: a pilot study. *Arthritis Res Ther* 2018;20:127.

149 Pistillo M, Bigley AB, Spielmann G, et al. The effects of age and viral serology on γδ T-cell numbers and exercise responsiveness in humans. *Cell Immunol* 2013;284:91–7.

150 Minuzzi LG, Rama L, Chupel MU, et al. Effects of lifelong training on senescence and mobilization of T lymphocytes in response to acute exercise. *Exerc Immunol Rev* 2018;24:72–84.